Study guide
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau)
Certified Genetic Counselor CGC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics
2 Domain 1A: Clinical Information
1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review
3 Domain 1B: Human Development
1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development
4 Domain 1C: Chromosomal & Contiguous Gene Syndromes
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)
5 Domain 1C: Hereditary Cancer Syndromes
1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition
6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions
1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework
7 Domain 2A: Pedigree & Risk Assessment
2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans
8 Domain 2B: Inheritance Principles
2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype
9 Domain 2B: Population Genetics & Variation
2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility
10 Domain 3A: Test Methodologies
3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics
11 Domain 3A: Variant Interpretation
3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework
12 Domain 3B: Testing Options
3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing
13 Domain 3C: Reproductive Risk Management
3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)
14 Domain 4A: Counseling Foundations
4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility
15 Domain 4A: Theories, Coping & Dynamics
4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics
16 Domain 4B: Communication & Education
4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making
17 Domain 5A–B: Finance & Client Resources
5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery
18 Domain 5C: Legal & Regulatory Requirements
5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing
19 Domain 5D: Professional Frameworks
5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education
20 Integration & Exam Strategy
6.1 Integrating Domains in Case-Based Practice & Exam Strategy
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau)
Key Takeaways Explain This Topic AI
Trisomy 21 (Down syndrome) is usually nondisjunction 47,XX,+21 or 47,XY,+21; Robertsonian translocation and mosaicism change recurrence counseling and parental karyotype recommendations
Maternal-age–related meiotic nondisjunction risk rises steeply after the mid-30s for autosomal trisomies; age framing must still include that most babies with Down syndrome are born to younger mothers because birth rates are higher
Turner syndrome (45,X and mosaics) features short stature, left-sided cardiac anomalies (coarctation/bicuspid aortic valve), renal anomalies, and ovarian dysgenesis with infertility risk
Klinefelter syndrome (47,XXY) presents with tall stature, hypogonadism, azoospermia/infertility, and variable learning or psychosocial concerns—often diagnosed in adolescence or infertility workups
Trisomy 18 (Edwards) and trisomy 13 (Patau) are associated with multiple congenital anomalies and high perinatal mortality; counseling centers on natural history, goals of care, and diagnostic confirmation (karyotype/CMA context)
Last updated: August 2026
1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau)
Quick Answer: Autosomal trisomies (21, 18, 13) and sex-chromosome aneuploidies (45,X; 47,XXY) are core CGC conditions. Know the karyotype , whether the mechanism is nondisjunction vs translocation vs mosaicism , how maternal age modifies autosomal trisomy risk, and the phenotype + counseling differences between viable sex-chromosome aneuploidy and lethal/near-lethal autosomal trisomies.
Domain 1C items rarely ask only “what is Down syndrome?” They ask you to interpret a karyotype string, explain recurrence after a translocation finding, counsel after NIPT/ultrasound, or distinguish mosaic from non-mosaic implications.
Mechanisms You Must Separate
Mechanism Typical karyotype example Counseling consequence
Meiotic nondisjunction 47,XX,+21 Recurrence slightly above population age-related risk; parental karyotypes usually normal
Robertsonian translocation 46,XX,der(14;21)(q10;q10),+21 Parental karyotyping required ; recurrence can be substantially higher if a parent is a balanced carrier
Mosaicism 47,XX,+21/46,XX Phenotype often milder/variable; prenatal mosaic results need careful confirmation strategy
Sex-chromosome aneuploidy 45,X or 47,XXY Different natural history and fertility counseling than autosomal trisomy
Mosaicism means two or more cell lines. Full aneuploidy implies essentially all examined cells share the aneuploid line (within laboratory limits). Do not equate “mosaic” with “benign”—severity phenotypes still occur—but expect greater variability and, prenatally, more interpretive complexity (including confined placental mosaicism after CVS).
Maternal-Age Risk Framing
Autosomal trisomy risk from meiotic nondisjunction rises with maternal age , especially after the mid-30s, because of longer oocyte arrest and increased meiotic error. Exam-ready counseling points:
Quote age-specific risks from current validated tables used in your practice setting—not memorized folklore numbers that drift over decades.
Still teach the epidemiology paradox: most infants with Down syndrome are born to women under 35 because more births occur in that age band.
Paternal age is not the primary driver of classic trisomy 21 nondisjunction counseling the way maternal age is.
Sex-chromosome aneuploidies have different age associations; do not automatically paste “advanced maternal age” scripts onto every 45,X or 47,XXY vignette.
Prenatal pathways (screening → diagnostic testing) belong with Domain 3 detail, but phenotype and karyotype literacy here is what makes those conversations coherent.
Down Syndrome (Trisomy 21)
Karyotype findings: ~95% are free trisomy 21 (47,XX,+21 or 47,XY,+21); ~2–3% Robertsonian translocation involving chromosome 21; ~2% mosaic.
Domain Essentials
Craniofacial / physical Upslanting palpebral fissures, epicanthal folds, flat nasal bridge, single transverse palmar crease, sandal-gap toes, hypotonia
- Cardiac Congenital heart disease common; atrioventricular septal defect (AVSD) is classic
- Development Intellectual disability (variable); early intervention improves functional outcomes
Medical surveillance Hypothyroidism, hearing/vision issues, atlantoaxial instability awareness, hematologic risk (including leukemia predisposition), early-onset Alzheimer disease in adulthood
Reproduction Reduced fertility, especially in males; reproductive counseling individualized
Translocation Down syndrome counseling trap: If the karyotype shows an unbalanced Robertsonian translocation, both parents should be offered karyotyping. A parent who is a balanced Robertsonian carrier has elevated recurrence risk; empiric risks depend on which parent carries the translocation and which chromosomes are involved. A de novo translocation in the child still warrants parental studies to confirm de novo status.
Prenatal counseling anchors: Increased NT, absent/hypoplastic nasal bone, abnormal serum analytes, or high-risk NIPT → offer diagnostic testing; discuss phenotype spectrum, medical comorbidities, and supports—not only “IQ number.” Postnatal counseling adds immediate newborn evaluation (echo, feeding/hypotonia, hematology) and connection to early intervention and syndrome-specific guidelines.
Turner Syndrome (Monosomy X Spectrum)
Karyotype: Classic 45,X; many individuals are mosaic (45,X/46,XX; 45,X/46,XY; structural X anomalies). Mosaic 45,X/46,XY raises distinct gonadal tumor surveillance issues—do not collapse all Turner counseling into one script.
- Feature cluster Clinical notes
- Growth Short stature; growth hormone often considered
- Lymphatic / neck Cystic hygroma prenatally; webbed neck, low posterior hairline postnatally
- Cardiac Left-sided lesions: bicuspid aortic valve , coarctation of the aorta ; lifelong aortopathy awareness
- Renal Horseshoe kidney and collecting-system anomalies
- Gonadal Ovarian dysgenesis → primary amenorrhea, infertility; hormone replacement planning
Cognition Typically not intellectual disability of Down-syndrome type; may have specific learning (e.g., visuospatial) differences
Prenatal: cystic hygroma, hydrops, cardiac/renal anomalies, or NIPT sex-chromosome flag. Postnatal/adolescent: short stature, delayed puberty, amenorrhea. Counsel cardiac imaging surveillance and reproductive options (egg donation, etc.) with sensitive infertility framing.
Klinefelter Syndrome (47,XXY)
- Feature Counseling relevance
- Habitus Taller stature, longer limbs; may be subtle in childhood
- Gonadal Small testes, hypogonadism, azoospermia/infertility common
- Endocrine Testosterone deficiency → bone density, energy, sexual function concerns
- Development Language/learning differences, psychosocial vulnerability in some
- Diagnosis timing Infancy (hypospadias/developmental clues), school age, or adult infertility clinic
Variants (48,XXXY, mosaics) exist; severity often correlates with additional X material. Prenatal 47,XXY counseling emphasizes the wide phenotypic range and available developmental/endocrine supports—avoid deterministic “always infertile / always disabled” language.
Edwards Syndrome (Trisomy 18) and Patau Syndrome (Trisomy 13)
Trisomy 18 (Edwards) Trisomy 13 (Patau)
Karyotype 47,XX,+18 or 47,XY,+18 (± mosaic/translocation rare mechanisms) 47,XX,+13 or 47,XY,+13 (± Robertsonian involving 13)
Growth Severe IUGR common IUGR common
Hallmark anomalies Clenched hands, overlapping fingers, rocker-bottom feet, omphalocele, CHD, choroid plexus cysts (soft marker context) Holoprosencephaly spectrum, cleft lip/palate, postaxial polydactyly, ocular anomalies, CHD
Prognosis High miscarriage/stillbirth and early mortality; rare longer-term survivors with profound disability Similarly high perinatal mortality; profound disability in survivors
Counseling focus Goals-of-care, accurate diagnostic confirmation, recurrence (usually age-related nondisjunction unless translocation) Same; parental karyotypes if translocation mechanism
Do not soft-pedal natural history, and do not strip autonomy: present medical facts, variability (especially mosaicism), and palliative versus interventional pathways as value-laden choices for the family.
Comparative Snapshot for Exam Recognition
- Syndrome Karyotype cue Highest-yield phenotype anchors
- Down +21 Hypotonia, AVSD, characteristic facies, ID
- Turner 45,X (± mosaic) Short stature, coarctation/BAV, ovarian dysgenesis
- Klinefelter 47,XXY Tall, hypogonadism, infertility
- Edwards +18 Clenched hands, rocker-bottom feet, severe anomalies, poor survival
- Patau +13 Holoprosencephaly, cleft, polydactyly, poor survival
- Putting It Together in a Session
Name the chromosome finding in plain language and technical karyotype terms.
State whether mechanism is likely nondisjunction, translocation, or mosaic —and what parental testing that implies.
Frame age-related risk honestly for autosomal trisomy without shaming reproductive timing.
Match prenatal vs postnatal agendas (pregnancy decision-making and anomaly counseling vs newborn/childhood surveillance and school supports).
Separate sex-chromosome aneuploidy natural history from trisomy 18/13 lethality narratives.
Mastering these five syndromes is the scaffold for later microarray and imprinting differentials: when the phenotype is “chromosomal” but the karyotype is normal, you move to CMA and methylation pathways—not to repeating a trisomy lecture.